News

Hospira's Remicade biosimilar wins large French contract with deep discount

Hospira continues to forge a new market reality around biosimilars, capturing wide swathes of market share with deep discounts for its biosimilar of Merck's arthritis blockbuster Remicade. Hospira has reportedly captured a public contract in France by offering a price that amounts to a 45% savings.

With vet drugs pumping, it's no wonder that pharma's eyeing M&A

What's with all the M&A rumors floating around in the animal health world? Just look at Zoetis' Apoquel and it's clear why Big Pharma names are keen to bolster their positions in the space.

Fast-growing Celgene snaps up Merck's abandoned NJ campus

Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old campus in Summit, NJ, adding the sprawling 1.3-million-square-foot complex to its already growing operations in the city.

Boehringer gets respiratory boost with batch of Spiolto nods in EU

When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged that payer arm-twisting happening stateside may make pricing tough. But now, the German drugmaker has nabbed some European approvals that should give the drug a lift.

Scientists dig up new evidence linking GSK's Pandemrix with narcolepsy

A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's now-withdrawn flu shot Pandemrix was associated with a spike in narcolepsy cases.

Eylea expected to keep delivering for Regeneron as Praluent starts to step up

Eye blockbuster Eylea has been churning out serious revenue growth for Regeneron since it hit the market, and now the company is inching closer to approval for its much-watched PCSK9 therapy. But what comes after that for the New York biotech? Analysts disagree.

Drug price increases hit record for Q2, with no sign of slowdown, analysts say

We've heard plenty of anecdotal reports about expensive drugs, from the long-running brouhaha over Gilead Sciences' hepatitis C drugs to the consternation about pricey new cancer meds. But occasionally, there's a broader view--and not surprisingly, that shows some impressive price inflation, too.

Bayer, J&J aim to protect Xarelto's market lead with focus on clinical data

Bayer and Johnson & Johnson know that right now, there's an impression out there that rival drug Eliquis--from Pfizer and Bristol-Myers Squibb--is superior to their next-gen clot-fighter Xarelto, despite their drug's market-share lead.

Bad news for AstraZeneca: FDA lays out roadmap for would-be Symbicort copycats

The FDA has issued AstraZeneca's least favorite form of draft guidance--the kind that helps other drugmakers develop copies of a blockbuster seller.

Novo Nordisk pulls Tresiba in Germany on pricing dispute

Germany's tough price negotiators went too far for Novo Nordisk. The Danish drugmaker is pulling its new diabetes drug Tresiba off the market after authorities said they'd price the long-acting basal insulin on par with old human insulin injections.

Biogen to build $1B plant, add 400 jobs in Switzerland

Biogen has looked at its pipeline of promising drug candidates for things like Alzheimer's disease and multiple sclerosis, measured that against its manufacturing network and decided it is going to need more capacity. The company announced on Tuesday that it will start with a $1 billion plant in Switzerland, where it expects to add 400 jobs.

Sworn to end doc payments by 2016, GSK still shelled out $15M last year

In 2013, GlaxoSmithKline CEO Andrew Witty pledged to end doctor payments by 2016 as part of an effort to clean up the company's image. But so far, little has changed in that department.

Feds want Novartis to cough up $3.4B in damages, fines in kickback case

Kickback allegations against Novartis just got scarier. After years of investigating the Swiss drugmaker, the Justice Department and 11 states are demanding almost $3.4 billion in damages and fines in a False Claims Act lawsuit nearing trial.

Pharma to EU officials: We need 'contingency' supply plans in case of 'Grexit'

Drugmakers are raising an alarm about shortages in Greece as the possibility of a "Grexit" looms. That "worst-case scenario" could put supplies in peril, the European Federation of Pharmaceutical Industries and Associations warned European Commission officials, with suddenly cheap meds in Greece diverted for sale at higher prices in neighboring EU countries.

Allergan to close plant in Iceland, lay off 300

Allergan Chairman Paul Bisaro has been quick to cut what he sees as redundant operations and people to help pay for his aggressive buying. Now, he has set his sights on the company's ancestry, with plans to whack a plant, and 300 jobs, in Iceland. 

Valeant can have Zoetis, Bayer says. We have our hands full already

Whether animal health leader Zoetis receives any more buyout offers after Valeant's reported approach remains to be seen. But if it does, Bayer's leaders insist a competing bid won't be coming from them.

Novartis tests performance pricing for much-anticipated Entresto launch

Novartis has big plans for its much-anticipated heart failure remedy Entresto. The Swiss drugmaker figures it can parlay impressive trial data on the drug into its biggest launch in years--perhaps ever.

Boehringer charges ahead with sale of U.S. generics biz with bids from Hikma, Mallinckrodt

Earlier this year, Boehringer Ingelheim said it was considering selling its U.S.-based generics business for up to €2 billion ($2.2 billion) to lighten its load and focus on drug development. Now, the company is moving one step closer to a sale as companies such as Hikma Pharmaceuticals, Mallinckrodt and Perrigo approach the bidding table.

AdverseEvents flags TB reports, blood-disorder cases linked to RA drugs

Drugmakers are eager to jump on the rheumatoid arthritis (RA) bandwagon, concentrating on tried-and-true treatments to bring in sales or developing new therapies to stave off looming biosimilars competition. But the meds come with their own set of safety issues, as both TNF-alpha treatments and non-TNF alpha drugs continue to generate troubling side effect reports.

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

Horizon Pharma isn't exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping sprees lately, leaving some analysts wondering just what's left worth buying in the space.